Hereditary angioedema and shared decision making

Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S55-S60. doi: 10.2500/aap.2020.41.200057.

Abstract

Clinical decision-making in hereditary angioedema (HAE) management involves a high degree of complexity given the number of therapeutic agents that are available and the risk for significant morbidity and potential mortality attributable to the disease. Given this complexity, there is an opportunity to develop shared decision-making (SDM) aids and/or tools that would facilitate the interactive participation of practitioners and patients in the SDM process. This article reviews the general constructs of SDM, the unmet need for SDM in HAE, and the steps necessary to create a SDM tool specific for HAE, and outlines the challenges that must be navigated to guide the establishment and widespread implementation of SDM in the management of HAE.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioedemas, Hereditary / diagnosis*
  • Angioedemas, Hereditary / therapy
  • Decision Making, Shared*
  • Humans
  • Patient Participation
  • Physician-Patient Relations